Renee Tannenbaum

Dr. Renee P.
Tannenbaum is a Head-Corporate Development at Bench International Search, Inc., an Independent Director at ANI Pharmaceuticals, Inc. and an Independent Director at Cardiff Oncology, Inc. She is on the Board of Directors at ANI Pharmaceuticals, Inc. and Cardiff Oncology, Inc. Dr. Tannenbaum was previously employed as a Vice President-Global Partnering by Halozyme Therapeutics, Inc., an Independent Director by Zogenix, Inc., a Head-Global Customer Excellence by AbbVie, Inc., an Independent Director by Sharps Compliance Corp., a President by Myrtle Potter & Co. LLC, a Chief Commercial Officer & Executive VP by Elan Pharmaceuticals, Inc., a Head-Global Commercial Operations Organization by Novartis Pharma AG, and a Professor by University of the Sciences in Philadelphia.
She also served on the board at Nordic Nanovector ASA, Cipher Pharmaceuticals, Inc., Immune Pharmaceuticals Ltd. and The Bay Area Bioscience Association.
She received her undergraduate degree from the University of Connecticut, an MBA from Temple University (Pennsylvania), a doctorate degree from the University of Connecticut and a doctorate degree from Philadelphia College of Pharmacy.